Table 4.
Linear regression analysis of baseline microRNAs relative expression to the functional improvement of the SMA patients at 6 months.
| microRNA | R 2 | Intercept | β | p‐value | Motor milestones scale |
|---|---|---|---|---|---|
| miR‐107 | 0.31 | 3.12 | 3.74 | 0.03 | CHOP‐INTEND |
| miR‐142‐5p | 0.36 | 3.08 | 4.17 | 0.01 | CHOP‐INTEND |
| miR‐328‐3p | 0.25 | 0.41 | 7.38 | 0.05 | CHOP‐INTEND |
| miR‐335‐5p | 0.36 | 2.83 | 4.49 | 0.01 | CHOP‐INTEND |
| miR‐423‐3p | 0.26 | 2.70 | 4.88 | 0.04 | CHOP‐INTEND |
| miR‐660‐5p | 0.27 | 3.88 | 2.57 | 0.04 | CHOP‐INTEND |
| miR‐139‐5p | 0.23 | −0.67 | 2.92 | 0.04 | HINE |
| miR‐181b‐5p | 0.32 | 0.76 | 1.47 | 0.02 | HINE |
| miR‐125a‐5p | 0.32 | 0.18 | 2.17 | 0.02 | HINE |
| miR‐23a‐3p | 0.27 | −2.44 | 4.95 | 0.03 | HINE |
Presented are unstandardised coefficients, model p value and the motor milestone scale used in the analysis. CHOP‐INTEND, Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders; HINE, Hammersmith Infant Neurological Examination Section 2; SMA, spinal muscular atrophy.